Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310138 | 0.92 | HPGD (0.53) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL310733 | 0.80 | L3MBTL3 (0.53) | MAPTALDH1A1L3MBTL1L3MBTL3TP53BP1 | |
| SCHEMBL18393128 | 0.80 | LMNA (0.72) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL311491 | 0.79 | ALDH1A1 (0.74) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL16284337 | 0.79 | HPGD (0.68) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL520231 | 0.78 | ALDH1A1 (0.76) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL309972 | 0.76 | MAPT (0.58) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL21761929 | 0.76 | LMNA (0.58) | MAPTHPGDALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL310306 | 0.74 | L3MBTL3 (0.55) | MAPTALDH1A1L3MBTL1L3MBTL3TP53BP1 | |
| SCHEMBL27913615 | 0.74 | HPGD (0.65) | MAPTHPGDALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | MAPT 2367/4885HPGD 1913/4885ALDH1A1 3410/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | MAPT 2367/4885HPGD 1913/4885ALDH1A1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.